Camurus AB (publ) (STO:CAMX)
Sweden
· Delayed Price · Currency is SEK 665.50
+5.50 (0.83%)
May 6, 2025, 4:00 PM CET
Camurus AB Revenue
In the year 2024, Camurus AB had annual revenue of 1.87B SEK with 8.78% growth. Camurus AB had revenue of 553.13M in the quarter ending December 31, 2024, with 47.67% growth.
Revenue
1.87B
Revenue Growth
+8.78%
P/S Ratio
20.72
Revenue / Employee
7.56M
Employees
256
Market Cap
38.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Bonesupport Holding AB | 997.85M |
| Vimian Group AB | 4.24B |
Camurus AB News
- 11 days ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 6 months ago - Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ... - GuruFocus
- 6 months ago - Q3 2024 Camurus AB Earnings Call Transcript - GuruFocus
- 7 months ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 11 months ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire